Skip to content
DataLookout
Menu

Changes this week

Changes detected in the 7 days to Nov 21, 2026

  1. Minor: Bioactive Resin Material Containing S-PRG Filler on White Spot Lesions Primary completion pushed from Aug 20, 2026 to Nov 20, 2026 Jordan University of Science and TechnologyNot applicable NCT07715942
  2. Minor: Ultrasound of the Spleen Utilizing Low-energy (Diagnostic Level) Insonification Primary completion pushed from Jan 7, 2027 to Jun 7, 2027 Northwell HealthNot applicable NCT06934096
  3. Minor: LiveWell mBc: Adapted Dialectical Behavioral Therapy Skills Training Primary completion pushed from Jan 31, 2027 to Apr 30, 2027 Medical University of South CarolinaNot applicable NCT07539649
  4. Minor: Genetic Markers of Susceptibility to Chemotherapy-induced Ovarian Damage in Cancer Patients Undergoing Ovarian Biopsy for Cryopreservation Primary completion pushed from Oct 2026 to Dec 2026 IRCCS Azienda Ospedaliero-Universitaria di BolognaNot specified NCT07270679
  5. Minor: Shoulder Denervation for Post Mastectomy Irradiation Shoulder Pain Primary and study completion pushed from Aug 1, 2026 to Dec 1, 2026 National Cancer Institute, EgyptNot applicable NCT07095569
  6. Minor: At-Home Transcutaneous Tibial Nerve Stimulation for Overactive Bladder in Rural Women Primary and study completion pushed from Oct 2026 to Mar 2027 Oregon Health and Science UniversityNot applicable NCT07178314
  7. Minor: Cognitive-Motor Exergame Training in Frail Adults Primary completion pushed from May 31, 2027 to Jun 30, 2027 Eleftheria GiannouliNot applicable NCT07074639
  8. Minor: Comparative Study of Embolic Agents · Subdural Hemorrhage Undergoing Middle Meningeal Artery (MMA) Embolization Primary completion pushed from Sep 2027 to Mar 2028 Sanford HealthNot applicable NCT07757113
  9. Minor: Subthreshold SCS or BMT Primary and study completion pushed from Aug 2026 to Dec 2026 Moens MaartenNot applicable NCT05169047
  10. Minor: Performance of Bioactive Bulk-Fill in Class II Restorations Primary completion pushed from Jun 30, 2027 to Nov 30, 2027 Bezmialem Vakif UniversityNot applicable NCT07547904
  11. Minor: Myofascial Exercise and Trigger Point Therapy for Non-Specific Low Back Pain Primary completion pushed from Oct 30, 2026 to Nov 30, 2026 National Yang Ming Chiao Tung UniversityNot applicable NCT07362420
  12. Minor: Transversalis Fascia Plane Block Versus Low-Dose Intrathecal Morphine for Open Inguinal Hernia Repair Primary completion pushed from Oct 23, 2026 to Dec 1, 2026 Hitit UniversityNot applicable NCT07695935
  13. Minor: Arterial Stiffness · Breast Cancer Primary and study completion dates pushed to Mar 1, 2027 Hacettepe UniversityNot applicable NCT07070778
  14. Minor: Exercise Intervention for Breast Cancer · Sarcopenia Primary and study completion pushed from May 30, 2027 to Aug 30, 2027 Capital Medical UniversityNot applicable NCT07732101
  15. Minor: Usability of a Chest-Strap Ambulatory ECG Monitor in Active Individuals in Comparison With a Traditional Ambulatory ECG Patch Monitor (MoMe ARC) Primary completion pushed from Feb 23, 2027 to Apr 23, 2027 Mayo ClinicNot specified NCT07772817
  16. Minor: RCT Study on the Effect of ETN on Live Birth Rate in DOR Patients Undergoing IVF-ET Primary completion pushed from Feb 1, 2031 to Apr 1, 2031 Huazhong University of Science and TechnologyNot applicable NCT07769684
  17. Minor: Efimosfermin Compared With Placebo · Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH) Trial sites expanded: 30 → 37 locations GlaxoSmithKlinePhase 3 NCT07701993
  18. Minor: Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) · Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Trial sites expanded: 133 → 138 locations SanofiPhase 3 NCT06290141
  19. Minor: GSK5784283 (Felcorekibart) Compared With Placebo · Moderate to Very Severe COPD (PERSIST COPD-1) Trial sites expanded: 7 → 11 locations GlaxoSmithKlinePhase 3 NCT07780669
  20. Minor: InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation Trial sites expanded: 121 → 293 locations GlaxoSmithKlinePhase 3 NCT07177339
  21. Minor: Lunsekimig Compared With Placebo · Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype Trial sites expanded: 314 → 322 locations SanofiPhase 3 NCT07190209
  22. Minor: Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec · Hemophilia A or B Respectively Trial sites expanded: 39 → 44 locations PfizerPhase 3 NCT05568719
  23. Minor: Intratumoral INT230-6 Compared to US Standard of Care · Soft Tissue Sarcomas (INVINCIBLE-3) Trial sites expanded: 17 → 20 locations Intensity Therapeutics, Inc.Phase 3 NCT06263231
  24. Minor: Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis Imperfecta Trial sites expanded: 4 → 9 locations AmgenPhase 3 NCT07366086
  25. Minor: Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04) Trial sites expanded: 11 → 18 locations Merck Sharp & Dohme LLCPhase 3 NCT07776691